title: Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
abstract: Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to examine 10-year outcomes for outpatients with schizophrenia who were receiving a conventional depot antipsychotic. Maintenance of outpatient status for 10 years was considered as a favorable outcome. From the initial sample of 1587 outpatients, 90 patients who were receiving a depot antipsychotic were included in this study (mean±SD, age 44.0±13.0 years; men, N=54). Haloperidol decanoate, fluphenazine decanoate, fluphenazine enanthate, and haloperidol decanoate plus fluphenazine enanthate were used in 53 (58.9%), 29 (32.2%), seven (7.8%), and one (1.1%) patients, respectively. These depot antipsychotics accounted for 36.9% of the total antipsychotic dosage on average. Seventeen patients (18.9%) successfully maintained outpatient status for 10 years. The most frequent reason for dropout was 'hospitalization' (N=49, 54.4%), followed by 'referral to another clinic/hospital' (N=9, 10.0%) and 'side effects' (N=7, 7.8%). As only 36.9% of the chlorpromazine equivalents were administered through depot antipsychotics, it is difficult to draw any firm conclusion. Still, the data suggest that even depot antipsychotics may not sufficiently prevent relapse in the treatment of schizophrenia.
authors.affiliation: Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. mcn41320@biglobe.ne.jp
authors.forename: Takahito
authors.initials: T
authors.lastname: Uchida
authors.forename: Takefumi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Sakurai
authors.forename: Chisa
authors.initials: C
authors.lastname: Tsutsumi
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Den
authors.forename: Masaru
authors.initials: M
authors.lastname: Mimura
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uchida
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005476:Fluphenazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D038801:International Classification of Diseases; D008137:Longitudinal Studies; D060046:Maintenance Chemotherapy / Q000009:adverse effects; D008297:Male; D008499:Medical Records; D055118:Medication Adherence; D008875:Middle Aged; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy* / Q000517:prevention & control; D055502:Secondary Prevention; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D004338:Drug Combinations; C033563:haloperidol decanoate; C011825:fluphenazine depot; D006220:Haloperidol; C017610:fluphenazine enanthate; D005476:Fluphenazine